Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy

被引:49
|
作者
Sun, Yating [1 ]
Zhao, Yarong [1 ]
Teng, Shanshan [1 ]
Hao, Fei [1 ]
Zhang, Huan [1 ]
Meng, Fanchao [1 ]
Zhao, Xiuting [1 ]
Zheng, Xiaolong [1 ]
Bi, Ye [1 ]
Yao, Yicheng [2 ]
Lee, Robert J. [1 ,3 ]
Teng, Lesheng [1 ]
机构
[1] Jilin Univ, Sch Life Sci, 2699 Qianjin Ave, Changchun, Jilin, Peoples R China
[2] Acalanes High Sch, Lafayette, CA USA
[3] Ohio State Univ, Coll Pharm, Div Pharmaceut, 500 W 12Th Ave, Columbus, OH 43210 USA
来源
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
folic acid; human serum albumin; nanoparticles; cabazitaxel; folic acid receptor; CONJUGATED NANOPARTICLES; FOLATE; DOCETAXEL; RESISTANT; DELIVERY; AGENT;
D O I
10.2147/IJN.S181296
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Background: We previously developed cabazitaxel (CTX)-loaded human serum albumin nanoparticles (NPs-CTX) via a self-assembly method, and these NPs showed efficacy in prostate cancer therapy. Many studies have shown that the levels of folic acid (FA) receptor on the surface of various tumor cells are high. Therefore, FA-modified NPs-CTX may have enhanced antitumor effects compared with unmodified NPs-CTX. Methods: NPs-CTX were first prepared via self-assembly, and FA was conjugated on the surface of NPs-CTX through the -NH2 groups of the NPs to produce FA-NPs-CTX. The FA-NPs-CTX were evaluated in tumor cells with high FA receptor (FR) expression in vitro and in vivo. Results: Both NPs-CTX and FA-NPs-CTX exhibited good stability and morphology. Drug release from the NPs was not affected by FA conjugation. Compared with CTX dissolved in a mixture of Tween 80 and 13% ethanol (w/w) at a ratio of 1: 4 (v/v) (Tween-CTX), the two nanoformulations had lower lytic activity against normal red blood cells. However, FA-NPs-CTX showed greater inhibition of tumor cells with overexpressed FR, compared with NPs-CTX, in the cytotoxicity experiments. Moreover, the cellular uptake of FA-NPs-CTX was enhanced through FR-mediated endocytosis in HeLa cells in vitro and HeLa xenograft tumors in vivo. Although Tween-CTX exhibited tumor growth inhibition similar to FA-NPs-CTX in vivo, this inhibition also caused adverse side effects; the median lethal dose (LD50) of Tween-CTX to mice was 5.68 mg/kg, while FA-NPs-CTX-treated mice survived at doses exceeding 400 mg/kg. Conclusion: The results showed that FA-NPs-CTX caused inhibition of tumor growth in a manner similar to that of Tween-CTX; however, the safety and tolerability of CTX were greatly improved by FA conjugation compared with those of Tween-CTX. In summary, FA-NPs-CTX have great potential in CTX delivery, and this formulation is a promising candidate for the treatment of cancers with high FR levels.
引用
收藏
页码:135 / 148
页数:14
相关论文
共 50 条
  • [1] Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form
    Anderson, KE
    Eliot, LA
    Stevenson, BR
    Rogers, JA
    PHARMACEUTICAL RESEARCH, 2001, 18 (03) : 316 - 322
  • [2] Formulation and Evaluation of a Folic Acid Receptor-Targeted Oral Vancomycin Liposomal Dosage Form
    Keith E. Anderson
    Lise A. Eliot
    Bruce R. Stevenson
    James A. Rogers
    Pharmaceutical Research, 2001, 18 : 316 - 322
  • [3] Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel
    Meng, Fanchao
    Sun, Yating
    Lee, Robert J.
    Wang, Guiyuan
    Zheng, Xiaolong
    Zhang, Huan
    Fu, Yige
    Yan, Guojun
    Wang, Yifan
    Deng, Weiye
    Parks, Emily
    Kim, Betty Y. S.
    Yang, Zhaogang
    Jiang, Wen
    Teng, Lesheng
    CANCERS, 2019, 11 (10)
  • [4] Receptor-Targeted Carboranyl Substituted Folic Acid for BNCT
    Takagaki, M.
    KURRI Progress Report, 2002,
  • [5] A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug
    Stevens, PJ
    Sekido, M
    Lee, RJ
    PHARMACEUTICAL RESEARCH, 2004, 21 (12) : 2153 - 2157
  • [6] Evaluation of a folic acid radioconjugate with improved in vivo properties for folate receptor-targeted radionuclide therapy of cancer diseases
    Cristina, Mueller
    Harriet, Struthers R.
    Roger, Schibli
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2011, 54 : S377 - S377
  • [7] Folic acid conjugated bovine serum albumin: An efficient smart and tumor targeted biomacromolecule for inhibition folate receptor positive cancer cells
    Nosrati, Named
    Abbasi, Reza
    Charmi, Jalil
    Rakhshbahar, Akram
    Aliakbarzadeh, Faezeh
    Danafar, Hossein
    Davaran, Soodabeh
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 117 : 1125 - 1132
  • [8] Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation
    Stevens, PJ
    Sekido, M
    Lee, RJ
    ANTICANCER RESEARCH, 2004, 24 (01) : 161 - 165
  • [9] Spectroscopic Study on Binding of Folic Acid to Human Serum Albumin
    Liu Hui-juan
    Li Peng
    Zhang Ya-dong
    Guo Cao
    Deng Jun-yuan
    Cai Jian-wei
    Liu Bo-li
    SPECTROSCOPY AND SPECTRAL ANALYSIS, 2009, 29 (07) : 1915 - 1919
  • [10] Influence of human serum albumin on photodegradation of folic acid in solution
    Vorobey, Pavel
    Steindal, Arnfinn Engeset
    Off, Morten Kristian
    Vorobey, Alexander
    Moan, Johan
    PHOTOCHEMISTRY AND PHOTOBIOLOGY, 2006, 82 (03) : 817 - 822